logo-large
  • Browse Categories

Publications by authors named "Emily Y Weng"

Claim this Profile
A
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J Moran, Emily Y Weng

Eur Respir Jยท October 2021


Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
© PubHawk
  • About PubHawk
  • Privacy Policy
  • Sitemap
Socials: